- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Officials of NanoBioMagnetics, Inc., (NBMI) today announced the issuance of its first patent by the U.S. Patent and Trademark Office. The patent, titled "Method and Apparatus for Improving Hearing," is based on the use of magnetically responsive nanoparticles implanted in the organs of the middle ear to drive tissue vibrations in the amplification of sound.
The technology was the first demonstration of the nanomechanical movement of tissue and operates in
principle much like a typical commercial electromagnetic hearing aid. Development and validation was
done during 2002 - 2004. The company now will move the technology through commercialization
Statistics of the National Institutes of Health indicate sensorineural hearing loss affects approximately 28 million Americans. The technology covered by today's patent has the potential to move hearing aid systems to smaller and totally implantable hearing devices, achieving more favorable patient economics, performance and compliance.
Charles Seeney, CEO and Founder of NBMI, and co-inventor on the patent, said "miniaturization of
hearing devices through ever smaller electronic components is part of an emerging trend based on
applying nanotechnology to human healthcare needs." A companion technology, based on the targeted
delivery of bioactive materials to the inner ear, continues under development. The company also has in progress major research collaborations assessing the tumor-specific delivery of cancer therapeutics, research for which is ongoing at the M D Anderson Cancer Center in Houston.
NBMI is a nanobiomaterials company, with core technology focused on designed structures of
magnetically responsive nanoparticles to cause or drive a desired physiological event. Its healthcare technologies are developed and validated through collaborations with academic and industrial institutions. NBMI's hearing amplification technology was developed in part through collaborations with the University of Oklahoma and the Massachusetts Eye and Ear Infirmary, an affiliate of Harvard Medical School.
Today's issuance is viewed as Oklahoma's first nanotechnology-based patent for a healthcare
About NanoBioMagnetics, Inc.
NanoBioMagnetics (NBMI) is a nanobiomaterials company pioneering an emerging area of nanomedicine referred to as organ-assisting-device (OAD) technologies. The company has developed a targeted therapeutic delivery methodology in which designed configurations of magnetically responsive nanoparticles (MNP), under the influence of external shaped magnetic fields, cause or drive a desired physiological event. MNP, single domain and superparamagnetic, respond to an applied magnetic field, returning to their normal state when the field is removed, in effect creating a "biomagnetic" switch. The company is applying this technological concept to a range of human health applications in collaborations with major research institutions across the country, where several scientific "firsts" have been achieved and published.
For more information, please click here
Charles E Seeney
Copyright © NanoBioMagnetics, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015
Take a trip through the brain July 30th, 2015
Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015
Quantum networks: Back and forth are not equal distances! July 28th, 2015
Smarter window materials can control light and energy July 22nd, 2015